Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00097357 · ClinicalTrials.gov registry record · Phase 2
BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,238
- Enrollment target
NCT00097357 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,238 participants.
The verdict
NCT00097357, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,238 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if BMS-562247 can prevent blood clots in the legs and lungs in men and women following unilateral total knee replacement surgery. The safety of this treatment will also be studied.
Interventions
- DRUG Apixaban
- DRUG Enoxaparin
- DRUG Warfarin
- DRUG Apixaban Placebo
- DRUG Enoxaparin Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,238 participants |
| Start Date | 2004-10 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00097357
The ClinicalTrials.gov registry entry for NCT00097357 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,238 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Apixaban is the first listed.
NCT00097357 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00097357 about?
NCT00097357 is a clinical study titled "BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery". The purpose of this study is to learn if BMS-562247 can prevent blood clots in the legs and lungs in men and women following unilateral total knee replacement surgery. The safety of this treatment will also be studied.
What is the current status of trial NCT00097357?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,238 participants. The study started on 2004-10. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00097357?
The interventions under investigation include: Apixaban (DRUG), Enoxaparin (DRUG), Warfarin (DRUG), Apixaban Placebo (DRUG), Enoxaparin Placebo (DRUG).
Who is sponsoring clinical trial NCT00097357?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.